Key Points
-
p53 is the most extensively studied tumor suppressor deregulated in most human cancers.
-
It is stimulated by various activating stimuli such as DNA damage, oncogene activation, stress and hypoxia.
-
Much effort has focused on studying activation of p53 for cancer therapy and various small-molecule activators have been identified so far. Some approaches for p53 activation for therapy include MDM2 inhibition and CDK inhibition.
-
Hyperactivation of the NF-κB pathway is seen in many cancers and inflammatory disorders.
-
The NF-κB pathway is activated by more 200 stimuli including viruses, cytokines, stress, bacterial or fungal products.
-
Efforts have focused on identifying inhibitors of the NF-κB pathway with over 785 inhibitors identified so far and counting.
-
There is a lot of interest in understanding the crosstalk between these two critical signalling pathways, which have been implicated in various human ailments.
-
With combination therapy emerging as the way forward in cancer therapy, small molecules that simultaneously target both these pathways by activating p53 and inhibiting NF-κB hold great promise for cancer therapy.
-
This Review focuses on candidate small molecules that have these dual desirable properties and suggests mechanism of action and prospects for future development.
Abstract
The p53 and nuclear factor-κB (NF-κB) pathways play crucial roles in human cancer, in which inactivation of p53 and hyperactivation of NF-κB is a common occurrence. Activation of p53 and inhibition of NF-κB promotes apoptosis. Although drugs are being designed to selectively activate p53 or inhibit NF-κB, there is no concerted effort yet to deliberately make drugs that can simultaneously do both. Recent results suggest that a surprising selection of small molecules have this desirable dual activity. In this Review we describe the principles behind such dual activities, describe the current candidate molecules and suggest mechanisms and approaches to their further development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000).
Vousden, K. H. & Lane, D. P. p53 in health and disease. Nature Rev. Mol. Cell Biol. 8, 275–283 (2007). This is a comprehensive overview of the various emerging roles of p53 and its relevance in not just protecting against cancer, but also its broader role in various diseases and overall survival of the organism.
Haupt, S. & Haupt, Y. Improving cancer therapy through p53 management. Cell Cycle 3, 912–916 (2004).
Vassilev, L. T. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13, 23–31 (2007).
Pahl, H. L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18, 6853–6866 (1999).
Gilmore, T. D. & Herscovitch, M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene 25, 6887–6899 (2006). This is a complete review of the various inhibitors of the NF-κB pathway: the nodes they target and their implications. An excellent read for identifying and characterizing molecules that can be used to simultaneously target multiple pathways.
Chen, L. F. & Greene, W. C. Shaping the nuclear action of NF-κB. Nature Rev. Mol. Cell Biol. 5, 392–401 (2004).
Perkins, N. D. Integrating cell-signalling pathways with NF-κB and IKK function. Nature Rev. Mol. Cell Biol. 8, 49–62 (2007). This is a comprehensive review discussing the crosstalk and integration of the NF-κB pathway with other signalling pathways and how these may contribute to cell fate.
Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K. & Sethi, G. Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 72, 1605–1621 (2006). This review discusses in detail the links between inflammation and cancer: the various critical players and their therapeutic implications.
Naugler, W. E. & Karin, M. NF-κB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18, 19–26 (2008).
Pikarsky, E. et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461–466 (2004).
Webster, G. A. & Perkins, N. D. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19, 3485–3495 (1999). The first study detailing the molecular mechanism of the crosstalk between the p53 and NF-κB pathways.
Tergaonkar, V. & Perkins, N. D. p53 and NF-κB crosstalk: IKKα tips the balance. Mol. Cell 26, 158–159 (2007).
Huang, W. C., Ju, T. K., Hung., M. C. & Chen, C. C. Phosphorylation of CBP by IKKα promotes cell growth by switching the binding preference of CBP from p53 to NF-κB. Mol. Cell 26, 75–87 (2007).
Tergaonkar, V., Pando, M., Vafa, O., Wahl, G. & Verma, I. p53 stabilization is decreased upon NFκB activation: a role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 1, 493–503 (2002).
Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Rev. Drug Discov. 3, 353–359 (2004).
Hopkins, A. L., Mason, J. S. & Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16, 127–136 (2006). This review discusses how rational design of promiscuous drugs with polypharmacology might be the way into the future.
Overington, J. P., Al Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nature Rev. Drug Discov. 5, 993–996 (2006). This is another interesting review that discusses the concept of polypharmacology. It addresses some critical issues and concerns on complexities of finding drug targets and their mechanism of action, such as the efficacy of drugs and the rate of target innovation.
Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770–1783 (2006).
Senderowicz, A. M. Small-molecule cyclin-dependent kinase modulators. Oncogene 22, 6609–6620 (2003).
Maccallum, D. E. et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65, 5399–5407 (2005).
Lu, W., Chen, L., Peng, Y. & Chen, J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 20, 3206–3216 (2001).
Rubbi, C. P. & Milner, J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22, 6068–6077 (2003).
McClue, S. J. et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102, 463–468 (2002).
Raynaud, F. I. et al. In vitro and in vivo pharmacokinetic–pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin. Cancer Res. 11, 4875–4887 (2005).
Whittaker, S. R., Walton, M. I., Garrett, M. D. & Workman, P. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 64, 262–272 (2004).
Raje, N. et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106, 1042–1047 (2005).
Alvi, A. J. et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 105, 4484–4491 (2005).
Monaco, E. A. III, Beaman-Hall, C. M., Mathur, A. & Vallano, M. L. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons. Biochem. Pharmacol. 67, 1947–1964 (2004).
Crescenzi, E., Palumbo, G. & Brady, H. J. Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy. Clin. Cancer Res. 11, 8158–8171 (2005).
Dey, A., Wong, E. T., Cheok, C. F., Tergaonkar, V. & Lane, D. P. R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death. Differ. 15, 263–273 (2008). An example of a compound, R -roscovitine, a CDK inhibitor that has the desirable property of targeting both the p53 and NF-κB pathways. This paper also describes the mechanism of action of R -roscovitine in detail.
Rossi, A. G. et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nature Med. 12, 1056–1064 (2006).
Bukanov, N. O., Smith, L. A., Klinger, K. W., Ledbetter, S. R. & Ibraghimov-Beskrovnaya, O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444, 949–952 (2006).
Demidenko, Z. N. & Blagosklonny, M. V. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res. 64, 3653–3660 (2004).
Kim, D. M. et al. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-α or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res. 63, 621–626 (2003).
Takada, Y. & Aggarwal, B. B. Flavopiridol inhibits NF-κB activation induced by various carcinogens and inflammatory agents through inhibition of IκBα kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J. Biol. Chem. 279, 4750–4759 (2004).
Gurova, K. V. et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors. Proc. Natl Acad. Sci. USA 102, 17448–17453 (2005). Another example of a small molecule that has the bifunctional property. This is a particularly interesting example of antimalarial compounds like quinacrine and their mechanism of action. The main advantage of these compounds is that they are already known to be well tolerated in humans.
Gurova, K. V., Hill, J. E., Razorenova, O. V., Chumakov, P. M. & Gudkov, A. V. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res. 64, 1951–1958 (2004).
Gorbachev, A. V., Gasparian, A. V., Gurova, K. V., Gudkov, A. V. & Fairchild, R. L. Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin inflammation. Eur. J. Immunol. 37, 2257–2267 (2007).
Wallace, D. J. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin. Arthritis Rheum. 18, 282–296 (1989).
Jung, K. J. et al. Small molecule inhibitor which reactivates p53 in HTLV-1 transformed cells. J. Virol. 82, 8537–8547 (2008).
Wang, W. et al. Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol. Ther. 4, 893–898 (2005).
Tovar, C. et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl Acad. Sci. USA 103, 1888–1893 (2006).
Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004).
Dey, A., Wong, E. T., Bist, P., Tergaonkar, V. & Lane, D. P. Nutlin-3 inhibits the NFκB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle 6, 2178–2185 (2007). Nutlins have been amongst the most extensively studied compounds activating p53. This study shows the potential of nutlin-3 to inhibit the NF-κB pathway as well. This is another example of bifunctional drugs, although in this case its effects are dependent on the p53 status of cells.
Dey, A., Verma, C. S. & Lane, D. P. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br. J. Cancer 98, 4–8 (2008).
Yang, Y. et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67, 9472–9481 (2007).
Tergaonkar, V., Bottero, V., Ikawa, M., Li, Q. & Verma, I. M. IκB kinase-independent IκBα degradation pathway: functional NF-κB activity and implications for cancer therapy. Mol. Cell. Biol. 23, 8070–8083 (2003).
Campbell, K. J., O'Shea, J. M. & Perkins, N. D. Differential regulation of NF-κB activation and function by topoisomerase II inhibitors. BMC Cancer 6, 101 (2006).
Campbell, K. J., Rocha, S. & Perkins, N. D. Active repression of antiapoptotic gene expression by RelA(p65) NF-κB. Mol. Cell 13, 853–865 (2004).
Campbell, K. J., Witty, J. M., Rocha, S. & Perkins, N. D. Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-κB transactivation. Cancer Res. 66, 929–935 (2006).
Tergaonkar, V., Correa, R. G., Ikawa, M. & Verma, I. M. Distinct roles of IκB proteins in regulating constitutive NF-κB activity. Nature Cell Biol. 7, 921–923 (2005).
Kau, T. R. & Silver, P. A. Nuclear transport as a target for cell growth. Drug Discov. Today 8, 78–85 (2003).
Rodriguez, M. S., Thompson, J., Hay, R. T. & Dargemont, C. Nuclear retention of IκBα protects it from signal-induced degradation and inhibits nuclear factor κB transcriptional activation. J. Biol. Chem. 274, 9108–9115 (1999).
Poiesz, B. J. et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl Acad. Sci. USA 77, 7415–7419 (1980).
Yoshida, M., Miyoshi, I. & Hinuma, Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl Acad. Sci. USA 79, 2031–2035 (1982).
Gessain, A. et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2, 407–410 (1985).
Nakamura, F. et al. HTLV-1 associated myelopathy in an HTLV-1 and HBV double carrier family: report of a case and the mode of vertical transmission of both viruses. J. Gastroenterol. Hepatol. 4, 387–390 (1989).
Osame, M. et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1, 1031–1032 (1986).
Jeong, S. J., Radonovich, M., Brady, J. N. & Pise-Masison, C. A. HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood 104, 1490–1497 (2004).
Pise-Masison, C. A. et al. Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J. Virol. 72, 1165–1170 (1998).
Pise-Masison, C. A., Radonovich, M., Sakaguchi, K., Appella, E. & Brady, J. N. Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J. Virol. 72, 6348–6355 (1998).
Pise-Masison, C. A. et al. Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-κB pathway and is dependent on p53 phosphorylation. Mol. Cell. Biol. 20, 3377–3386 (2000).
Dasgupta, A., Jung, K. J., Jeong, S. J. & Brady, J. N. Inhibition of methyltransferases results in induction of G2/M checkpoint and programmed cell death in human T-lymphotropic virus type 1-transformed cells. J. Virol. 82, 49–59 (2008).
Schwerk, C. & Schulze-Osthoff, K. Methyltransferase inhibition induces p53-dependent apoptosis and a novel form of cell death. Oncogene 24, 7002–7011 (2005).
Jeong, S. J., Pise-Masison, C. A., Radonovich, M. F., Park, H. U. & Brady, J. N. Activated AKT regulates NF-κB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 24, 6719–6728 (2005).
de Moraes, E., Dar, N. A., Moura Gallo, C. V. & Hainaut, P. Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int. J. Cancer 121, 929–937 (2007).
Swamy, M. V., Herzog, C. R. & Rao, C. V. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res. 63, 5239–5242 (2003).
Schonthal, A. H. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br. J. Cancer 97, 1465–1468 (2007).
Li, H. L. et al. Changes of NF-κB, p53, Bcl-2 and caspase in apoptosis induced by JTE-522 in human gastric adenocarcinoma cell line AGS cells: role of reactive oxygen species. World J. Gastroenterol. 8, 431–435 (2002).
Aggarwal, B. B. & Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71, 1397–1421 (2006).
Guzman, M. L. et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110, 4427–4435 (2007).
Oka, D. et al. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-κB. Int. J. Cancer 120, 2576–2581 (2007).
Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nature Rev. Drug Discov. 6, 273–286 (2007).
Teodoro, J. G., Evans, S. K. & Green, M. R. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J. Mol. Med. 85, 1175–1186 (2007).
Naugler, W. E. & Karin, M. NF-κB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18, 19–26 (2008).
Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008).
Ingber, D. et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555–557 (1990).
Yeh, J. R., Mohan, R. & Crews, C. M. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc. Natl Acad. Sci. USA 97, 12782–12787 (2000).
Mauriz, J. L. et al. TNP-470 inhibits oxidative stress, nitric oxide production and nuclear factor κB activation in a rat model of hepatocellular carcinoma. Free Radic. Res. 37, 841–848 (2003).
Ozes, O. N. et al. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401, 82–85 (1999).
Sizemore, N., Leung, S. & Stark, G. R. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-κB p65/RelA subunit. Mol. Cell. Biol. 19, 4798–4805 (1999).
Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489–501 (2002).
Lindsley, C. W. et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15, 761–764 (2005).
Rocha, S., Campbell, K. J. & Perkins, N. D. p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor. Mol. Cell 12, 15–25 (2003).
Ryan, K. M., Ernst, M. K., Rice, N. R. & Vousden, K. H. Role of NF-κB in p53-mediated programmed cell death. Nature 404, 892–897 (2000).
Schumm, K., Rocha, S., Caamano, J. & Perkins, N. D. Regulation of p53 tumour suppressor target gene expression by the p52 NF-κB subunit. EMBO J. 25, 4820–4832 (2006).
Gudkov, A. V. & Komarova, E. A. Prospective therapeutic applications of p53 inhibitors. Biochem. Biophys. Res. Commun. 331, 726–736 (2005).
Komarov, P. G. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733–1737 (1999).
Bernardi, R. & Pandolfi, P. P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nature Rev. Mol. Cell Biol. 8, 1006–1016 (2007).
de Stanchina, E. et al. PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 13, 523–535 (2004).
Wu, W. S. et al. Promyelocytic leukemia protein sensitizes tumor necrosis factor α-induced apoptosis by inhibiting the NF-κB survival pathway. J. Biol. Chem. 278, 12294–12304 (2003).
Weisz, L. et al. Mutant p53 enhances nuclear factor κB activation by tumor necrosis factor α in cancer cells. Cancer Res. 67, 2396–2401 (2007).
Farooqui, A. A., Ong, W. Y. & Horrocks, L. A. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol. Rev. 58, 591–620 (2006).
Lee, K. C. et al. Detection of the p53 response in zebrafish embryos using new monoclonal antibodies. Oncogene 27, 629–640 (2008).
Correa, R. G. et al. Zebrafish IκB kinase 1 negatively regulates NF-κB activity. Curr. Biol. 15, 1291–1295 (2005).
Kashatus, D., Cogswell, P. & Baldwin, A. S. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev. 20, 225–235 (2006).
Acknowledgements
The authors apologize to all those whose primary work could not be cited owing to space limitations. This work is supported by the Agency for Science, Technology and Research (A*STAR), Singapore. D.P.L. is a Gibb Fellow of Cancer Research UK.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Related links
FURTHER INFORMATION
Rights and permissions
About this article
Cite this article
Dey, A., Tergaonkar, V. & Lane, D. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways. Nat Rev Drug Discov 7, 1031–1040 (2008). https://doi.org/10.1038/nrd2759
Issue Date:
DOI: https://doi.org/10.1038/nrd2759
This article is cited by
-
Clinical significance of oxidative stress markers as angioinvasion and metastasis indicators in papillary thyroid cancer
Scientific Reports (2023)
-
P53 vs NF-κB: the role of nuclear factor-kappa B in the regulation of p53 activity and vice versa
Cellular and Molecular Life Sciences (2020)
-
Anti-survivin effect of the small molecule inhibitor YM155 in RCC cells is mediated by time-dependent inhibition of the NF-κB pathway
Scientific Reports (2018)
-
Sesquiterpene lactone! a promising antioxidant, anticancer and moderate antinociceptive agent from Artemisia macrocephala jacquem
BMC Complementary and Alternative Medicine (2017)
-
A novel 4,6-disubstituted-1,2,4-triazolo-1,3,4-thiadiazole derivative inhibits tumor cell invasion and potentiates the apoptotic effect of TNFα by abrogating NF-κB activation cascade
Apoptosis (2017)